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Objective: Diabetes mellitus is a risk factor for death after coronary artery
bypass grafting. Its relative risk may be related to the level of perioperative
hyperglycemia. We hypothesized that strict glucose control with a continuous
insulin infusion in the perioperative period would reduce hospital mortality.
Methods: All patients with diabetes undergoing coronary artery bypass
grafting (n  3554) were treated aggressively with either subcutaneous
insulin (1987-1991) or with continuous insulin infusion (1992-2001) for
hyperglycemia. Predicted and observed hospital mortalities were com-
pared with both internal and external (Society of Thoracic Surgeons 1996)
multivariable risk models.
Results: Observed mortality with continuous insulin infusion (2.5%, n 
65/2612) was significantly lower than with subcutaneous insulin (5.3%,
n 50/942, P .0001). Likewise, glucose control was significantly better
with continuous insulin infusion (177 30 mg/dL vs 213 41 mg/dL, P .0001).
For internal comparison, multivariable analysis showed that continuous insulin
infusion was independently protective against death (odds ratio 0.43, P  .001).
Conversely, cardiogenic shock, renal failure, reoperation, nonelective operative
status, older age, concomitant peripheral or cerebral vascular disease, decreasing
ejection fraction, unstable angina, and history of atrial fibrillation increased the risk
of death. For external comparison, observed mortality with continuous insulin
infusion was significantly less than that predicted by the model (observed/expected
ratio 0.63, P  .001). Multivariable analysis revealed that continuous insulin infusion
added an independently protective effect against death (odds ratio 0.50, P  .005)
to the constellation of risk factors in the Society of Thoracic Surgeons risk model.
Conclusion: Continuous insulin infusion eliminates the incremental increase in in-
hospital mortality after coronary artery bypass grafting associated with diabetes. The
protective effect of continuous insulin infusion may stem from the effective metabolic
use of excess glucose to favorably alter pathways of myocardial adenosine triphosphate
production. Continuous insulin infusion should become the standard of care for glyco-
metabolic control in patients with diabetes undergoing coronary artery bypass grafting.
Diabetes mellitus (DM) is a well-established risk factor for deathafter coronary artery bypass grafting (CABG).1-3 DM has beenrecognized as an independent risk factor for CABG-related deathsince the inception of the Society of Thoracic Surgeons (STS)national risk model in 1991.1 DM is present in 2.5% of thepopulation in the United States,4 but its national prevalence
among patients undergoing CABG is as high as 28%,1 making it an important
component of the cardiac surgical milieu.
DM is associated with higher incidences of preoperative comorbidities, including
obesity, small vessel coronary artery disease, more severe and extensive atheroscle-
rosis, peripheral vascular disease, renal insufficiency, hypertension, and increased
rates of life-threatening postoperative infection. Conventional wisdom has held that
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the increase in CABG mortality associated with DM is
related to the increased incidence of these comorbid factors
associated with DM.3,5,6 However, this may not be the case.
In the Diabetes and Insulin-Glucose Infusion in Acute
Myocardial Infarction study, Malmberg and associates7
showed that survival rates of patients with DM who had
acute myocardial infarctions (MIs) were improved when
they were treated with insulin infusions designed to achieve
normoglycemia. In this study absolute survival rates were
improved by 11% at 1 year and by 15% at 3.5 years. These
authors asserted that glycometabolic control at the time of
acute infarction played a leading role in the observed im-
provement in outcomes.8 These findings were corroborated
in a prospective randomized trial by the Estudios Cardio-
logicos Latinoamerica collaborative group, which showed a
66% relative reduction in post-MI mortality with insulin and
glucose metabolic modulation in addition to vessel reperfu-
sion.9
Studies with glucose-insulin-potassium (GIK) metabolic
modulation in patients undergoing CABG have to date
failed to reveal a survival advantage,10,11 even for patients
with DM.12 However, it has been shown that oxidative
glycometabolic adenosine triphosphate (ATP) generation is
impaired in the ischemic diabetic myocardium.13 Patients
with DM are known to have increased risk of low cardiac
output syndrome and intra-aortic balloon pump use after
CABG. We have previously shown that the relative risk of
death for a given patient with DM is independently related
to the level of perioperative hyperglycemia.14 Thus poor
glycometabolic control may be detrimental to myocardial
function and clinical outcome.
Since January 1987 all patients with DM undergoing
heart surgery at Providence St Vincent Medical Center have
been enrolled into our ongoing prospective interventional
study of the effects of hyperglycemia, and its pharmacologic
reduction, on morbidity and mortality. This phase of the
project was designed to test the hypothesis that a continuous
intravenous insulin infusion (CII) in the perioperative pe-
riod would reduce mortality among patients with DM un-
dergoing CABG.
Methods
Patients
Between January 1987 and December 2001, a total of 14,051
patients underwent isolated CABG at St Vincent Medical Center.
All patients with DM who underwent CABG alone, without a
concomitant procedure (n  3554, 26% of all patients undergoing
CABG) were included in this study. Patients who underwent
CABG combined with other operations (valve replacement or
repair, aortic operations, closure of septal defects, or transmyocar-
dial laser revascularization) were excluded from the current study.
All isolated on-pump CABG procedures at this institution are
performed with short periods of intermittent fibrillation without the
use of cardioplegia as a method of myocardial protection. The
conditions and conduct of cardiopulmonary bypass remained con-
stant throughout the study period.
All patients in the St Vincent Diabetic Project undergo pro-
spective measurement of blood glucose levels (by finger stick or
arterial line drop sample) every 30 minutes to 2 hours in the
perioperative period. Average daily glucose levels, along with
known preoperative risk factors for morbidity or mortality, were
routinely entered into a database for later analysis. These variables
included the following:
1. Demographic variables were age, sex, height, weight, and
type of preoperative diabetic control (insulin, oral agents,
diet, or none).
2. Historical variables were hypertension, congestive heart
failure, renal failure, renal insufficiency, chronic obstructive
pulmonary disease, pulmonary hypertension, smoking his-
tory, current smoking status, recent cerebrovascular accident
(within 2 weeks), remote cerebrovascular accident (2
weeks before surgery), peripheral vascular disease, and New
York Heart Association functional class.
3. Cardiovascular variables were left main trunk disease, num-
ber of diseased vessels, unstable angina, ejection fraction,
acute MI, previous MI, timing of previous MI, history of
atrial fibrillation, cardiogenic shock, percutaneous translu-
minal angioplasty, and intra-aortic balloon pump insertion.
4. Preoperative laboratory variables were serum glucose, albu-
min, hemoglobin A1C, and creatinine levels.
5. Preoperative medications noted were diuretics, digoxin, in-
travenous nitrates, and steroids.
6. Intraoperative variables were STS operative status (elective,
urgent, emergency, or salvage), reoperative cardiac proce-
dures, and cardiopulmonary bypass time.
7. Postoperative variables were total units of blood transfused,
prolonged (48 hours) intubation, inotropic use for longer
than 48 hours, epinephrine use, new-onset atrial fibrillation,
mediastinitis, and seminal cause of death15 (hemorrhage,
arrhythmia, pump failure, respiratory failure, neurologic,
infection, or renal failure).
Definitions
Definitions from the STS database committee were used for all
variables common with that database. Definitions of other vari-
ables unique to this study included the following:
1. DM included all patients admitted to the hospital with a
comorbid diagnosis of DM. Patients without a previous
diagnosis of DM but with persistently elevated postopera-
tive glucose levels (200 mg/dL) and a discharge require-
ment for pharmacologic glycemic control were also in-
cluded. These patients were identified as patients with newly
diagnosed DM during their admission for CABG.
2. Average postoperative glucose level was the composite av-
erage of the daily mean glucose levels from the day of
surgery and the first and second postoperative days (PODs).
This variable was used as the primary indicator of the
pharmacologic effectiveness of hyperglycemic treatment in
this study.
3. Mortality or death referred to any in-hospital death occur-
ring at any time during admission for CABG surgery after
the start of that surgery.
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4. Cardiac-related mortality referred to all deaths in which
arrhythmia or pump failure was identified as the seminal
cause of death.
Study Groups
All patients with DM were divided into two sequential groups
according to the type of perioperative glycemic control that they
received.
Subcutaneous insulin group. Patients operated on between
January 1987 and September 1991, the subcutaneous insulin (SQI)
group (n  942), received subcutaneous insulin injections every 4
hours in a directed attempt to maintain blood glucose levels below
200 mg/dL. Sliding scale dosage of insulin was titrated to each
patient’s glycemic response during the previous 4 hours. These
sliding scale SQI injections were continued every 4 hours through-
out the patients’ hospital course, even after the resumption of their
preoperative glucose control regimen.
CII group. All patients with DM undergoing CABG operated
on between October 1991 and December 2001, the CII group (n
2612), received a CII infusion titrated per protocol in the periop-
erative period (Portland protocol).16 The current Portland protocol
(Appendix) was implemented in gradual steps designed to main-
tain patient safety, prevent hypoglycemia, and ensure nursing
comfort and compliance. This protocol prescribes insulin initia-
tion, infusion and titration rates, and glucose testing frequency
requirements to safely maintain a patient’s blood glucose between
desired target levels. Between 1991 and 1998, the target glucose
range was 150 to 200 mg/dL; in 1999 it was dropped to 125 to 175
mg/dL and in 2001 was again lowered to 100 to 150 mg/dL. From
1991 to 1995, the Portland protocol was used after the operation
only in the intensive care unit (ICU) and was stopped when the
patient was transferred to the telemetry unit. In January 1996, the
protocol was expanded with initiation in the operating room (be-
fore sternotomy and after induction of anesthesia, with continua-
tion during cardiopulmonary bypass) and uniform continuation
until 7 AM of the third POD, even for patients who had transferred
out of the ICU.
Serum potassium levels were maintained between 4.0 and 5.5
mmol/L through the administration of exogenous potassium. In the
ICU this was accomplished through the intravenous administration
of potassium according to a standardized protocol. Oral potassium
supplementation was given to maintain these levels once patients
were tolerating enteral nutrition and their CII and glucose levels
had stabilized.
Data Analysis
In-hospital mortality was the primary end point of this study.
Patient groups were analyzed on an intent-to-treat basis. According
to this method, intraoperative and first POD deaths were included
in the end point analysis even though those patients did not
complete the 3-day SQI or CII treatment protocols. This was
considered to be the most rigorous method to test our hypothesis.
An internal logistic regression model was developed to deter-
mine the effect of perioperative hyperglycemic treatment method
(SQI vs CII) on operative mortality after adjustment for other
known preoperative risk factors. The external risk model was taken
from the 1996 STS risk algorithm.2 The 1996 model was chosen
because that year contained the median patient of the study’s data
set. By means of this nationally recognized risk assessment, all
patients were assigned an expected probability of death. Predicted
and observed hospital mortalities were then compared, along with
the observed/expected risk ratios. The composite STS risk score
was calculated as the logit of the probability of death.
Univariate analyses between groups were done with t tests and
2 analyses. The Bonferroni correction was applied to adjust for
multiple comparisons between groups. Stepwise logistic regres-
sion was used to produce risk models for hospital death. to mea-
sure model discrimination, c-statistics (area under the receiver
operating characteristic curve) were used, and the Hosmer-Leme-
show statistic was used to measure calibration.17 The purpose was
to make internal comparisons rather than to produce a prediction
equation for use outside of this data set. Thus all patients were
used, rather than separating the data into training and testing
subsets or applying shrinkage methods to the coefficients. All
statistical analyses were performed with SPSS software (version
10.0; SPSS, Inc, Chicago, Ill).
Results
Between January 1987 and December 2001, a total of
14,051 patients underwent isolated CABG at St Vincent
Hospital with an overall mortality of 2.8% (n 388/14051).
Of these patients, 3554 (26%) had DM and were enrolled in
this study. The two study groups into which these patients
with DM undergoing CABG were divided were slightly
heterogeneous (Table 1).
CII was extremely effective in controlling postoperative
hyperglycemia. Mean postoperative glucose levels were
significantly lower in the CII group than in the SQI group on
the day of surgery through the second POD (Table 1). As
the Portland CII protocol was implemented in a series of
increasingly aggressive steps (see “Methods”), postopera-
tive glycemic control gradually improved (Figure 1).
The postoperative mortality for all patients with DM
undergoing CABG in this study was 3.2% (n  115/3554).
In-hospital death occurred at a median of 11.2  13 PODs
(range 0-68 days). The overall mortality in the CII group of
2.5% (n  65/2612) was significantly lower than that in the
SQI group (5.3%, n  50/942, P  .0001). This analysis
was performed on an intent-to-treat basis. One could make
the argument that those patients who died in the operating
room or within 24 hours of surgery (n  24) had “operative
catastrophes” and did not survive long enough to derive a
benefit from initiation of CII therapy. If our analysis were to
be evaluated on an actual treatment (as opposed to intent-
to-treat) basis, SQI mortality would have been 4.5% (n 
42/934), and CII mortality would have been 1.9% (n 
49/2596, P  .0001).
Cause of Death
The seminal causes of death for each of the 115 patients
who died were pump failure in 54% (n 62), arrhythmia in
17% (n  20), neurologic causes in 19% (n  22), respi-
ratory failure in 5% (n  6), renal failure in 3% (n  3),
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TABLE 1. Characteristics of study groups
Variable All SQI CII P value
No. of patients 3554 942 2612
Preoperative
Age (y, mean  SD) 64 10 65 9 64 10
Male (No.) 2316 (65%) 603 (64.0%) 1713 (65%)
Diabetic control (No.)
Insulin 1171 (33%) 314 (33%) 857 (33%)
Oral agent 1784 (50%) 455 (48%) 1329 (51%)
Diet only 405 (11%) 108 (12%) 297 (11%)
No prescription 194 (6%) 65 (7%) 129 (5%)
Smoking (No.) 880 (25%) 150 (16%) 730 (28%) .001
Hypertension (No.) 2426 (68%) 545 (58%) 1881 (72%) .001
Congestive heart failure (No.) 738 (21%) 222 (24%) 516 (20%)
Renal failure (No.) 141 (4.0%) 47 (5.1%) 94 (3.6%)
Renal insufficiency (No.) 234 (6.6%) 29 (3.1%) 205 (7.9%) .001
Peripheral vascular disease (No.) 649 (18%) 160 (17%) 489 (19%)
Cerebral vascular disease (No.) 315 (9%) 97 (11%) 218 (9%)
Chronic obstructive pulmonary disease (No.) 365 (11%) 74 (8%) 291 (11%)
Pulmonary hypertension (No.) 71 (2.0%) 14 (1.5%) 58 (2.2%)
Body mass index (kg/m2, mean  SD) 29.7 5.6 28.4 5.1 30.2 5.7 .001
Ejection fraction (%, mean  SD) 54.9 16 53.2 17 55.4 15
Preoperative intra-aortic balloon pump (No.) 63 (1.8%) 23 (2.6%) 40 (1.6%)
No. of diseased vessels (mean  SD) 2.6 0.6 2.6 0.6 2.6 0.6
Left main trunk 50% (No.) 545 (16%) 117 (13%) 428 (17%)
Previous MI (No.) 1926 (55%) 541 (58%) 1385 (53%)
Acute MI (No.) 747 (22%) 201 (22%) 546 (21%)
Percutaneous transluminal angioplasty (No.) 71 (2.1%) 27 (3.0%) 44 (1.7%)
Intravenous nitrates (No.) 745 (22%) 165 (19%) 580 (23%)
Digoxin (No.) 504 (15%) 185 (21%) 319 (12%) .001
Diuretics (No.) 1163 (34%) 363 (41%) 800 (31%) .001
Steroids (No.) 154 (4.3%) 33 (3.5%) 121 (4.6%)
Albumin (g/dL, mean  SD) 3.7 0.5 3.9 0.6 3.6 0.5 .001
Admission glucose (mg/dL, mean  SD) 171 60 176 63 170 59
Perioperative
Postoperative blood glucose (mg/dL, mean  SD)
Average 187 37 214 41 177 30 .001
Day of surgery 201 53 242 61 187 41 .001
POD 1 181 34 205 36 173 28 .001
POD 2 181 40 195 39 176 39 .001
Mediastinitis (No.) 33 (0.9%) 17 (1.8%) 16 (0.6%) .05
Reoperative sternotomy (No.) 416 (12% 138 (15% 278 (11% .04
Urgency of operation (No.) .002
Elective 1866 (53%) 469 (50%) 1397 (53%)
Urgent 146 (41%) 400 (42%) 1067 (41%)
Emergency 187 (5%) 52 (5.5%) 135 (5.2%)
Salvage 38 (1%) 23 (2.4%) 15 (0.6%)
Internal thoracic artery use (No.) .01
0 929 (26%) 352 (37%) 577 (22%)
1 2571 (72%) 589 (63%) 1982 (76%)
2 52 (1.5%) 1 (0.1%) 51 (2.0%)
Off-pump procedure 37 (1.0%) 0 (0%) 37 (1.4%) .01
Cardiopulmonary bypass time (min, mean  SD) 80.5 34 85.2 39 78.7 32 .001
Transfused packed red blood cells (units, mean  SD) 1.8 5.9 2.2 2.9 1.6 6.7
Epinephrine use (No.) 137 (3.9%) 33 (3.5%) 104 (4.0%)
Inotropes 48 h (No.) 294 (8.3%) 99 (10.5%) 195 (7.5%)
Low cardiac output syndrome 370 (11%) 115 (13%) 225 (10%) .09
Ventilation 48 h (No.) 192 (5.4%) 61 (6.5%) 131 (5.0%)
New-onset atrial fibrillation 729 (21%) 253 (27%) 476 (18%) .001
Length of stay (d, mean  SD) 8.6 5.7 10.4 6.6 8.0 5.3 .001
Observed deaths (No.) 115 (3.2%) 53 (5.3%) 67 (2.5%) .001
STS-predicted deaths (No.) 4 4.7 3.8
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hemorrhage in 1% (n  1), and infection in 1% (n  1).
Cardiac-related causes accounted for most (71%, n  85/
120) of the deaths in this series. Cardiac-related mortality
was significantly greater in the SQI group (4.2%, n 
40/942) than in the CII group (1.6%, n  42/2612; P 
.001), implicating a myocardial mechanism of action for
CII. There was no difference between the two groups in the
incidence of deaths from noncardiac causes (1.1% [n 
10/942] vs 0.9% [n 23/2612], P .5). Conversely stated,
the reduction in operative mortality seen with CII was
accounted for solely by a reduction in cardiac-related
deaths.
An analysis of mortality according to glucose quantile is
presented in Figure 2. This shows a highly significant rela-
tionship (P  .001) between mortality and postoperative
glucose levels rising above 175 mg/dL. Figure 2 also reveals
that the increase in overall mortality was principally ac-
counted for by an increase in cardiac-related mortality.
Non–cardiac-related mortality did not increase as postop-
erative glucose levels rose (P  .9).
Internal Multivariable Analysis of Mortality
An internal logistic regression model that was based solely
on these data was developed to determine the effect of CII
on operative mortality after adjustment for other known
preoperative risk factors (Table 2). Treatment of hypergly-
cemia with CII independently reduced the odds of mortality
by a factor of 57% (odds ratio 0.43, P  .001). Cardiogenic
shock, renal failure, reoperation, increasing urgency of op-
eration, increasing age, a history of peripheral or cerebral
vascular disease, decreasing ejection fraction, unstable an-
gina, and a history of atrial fibrillation were all found to
increase the risk of death. The c-statistic for this model was
0.874, indicating high predictability for post-CABG mor-
tality among patients with DM.
Several other preoperative variables, known from other
logistic regression models to predispose toward death after
CABG, did not enter this model. These included gender
(P  .8), congestive heart failure (P  .2), left main trunk
disease (P  .2), previous MI (P  .8), acute MI (P  .5),
preoperative intra-aortic balloon pump (P  .5), previous
percutaneous transluminal angioplasty (P  .3), chronic
obstructive pulmonary disease (P .2), intravenous nitrates
(P  .4), diuretic (P  .4), digoxin (P  .2), pulmonary
hypertension (P  .3), and steroid use (P  .9). Impor-
tantly, neither date of operation (P  .6) nor year of oper-
ation (P  .8) was found to independently influence mor-
tality.
Postoperative epinephrine use and deep sternal infections
have both been shown to increase glucose levels and mor-
tality. They are, however, not “preordained” variables and
should not be used to infer risk in predictive models. None-
theless, when added into the internal model they were both
highly significant (P  .001). When these additions were
made to this model, they actually increased the protective
significance of CII (P  .001, odds ratio 0.36), with history
of atrial fibrillation becoming nonsignificant and ejection
Figure 1. Scattergram of average postoperative glucose levels of all 3554 patients with DM undergoing CABG
according to date of surgery. Smoothed local regression (Loess) curve is superimposed. Initiation of Portland
protocol is marked by vertical line. Note gradual reduction of glucose levels with time.
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fraction, cardiogenic shock, and reoperation all slightly
decreasing in significance. The c-statistic of this postoper-
atively enhanced model was improved to 0.9.
When the continuous variable of average postoperative
blood glucose level was entered into the logistic regression
as a potentially more accurate reflection of glycometabolic
control, it displaced the categoric variable of CII from the
equation, leaving all other variables in place (P  .001,
odds ratio 1.018 per 1 mg/dL, c-statistic 0.886). This again
implies that CII is exerting a protective effect on mortality
through a direct reduction of hyperglycemia, which may
reflect an underlying detrimental metabolic defect within
the postischemic diabetic myocardium.
The individual daily average glucose levels from the day
of surgery (P  .003, odds ratio 1.006 per 1 mg/dL) and
from the first (P  .001, odds ratio 1.013 per 1 mg/dL) and
second (P  .015, odds ratio  1.018 per 1 mg/dL) PODs
were each significant independent predictors of death when
entered into the model in lieu of the composite 3-day
average glucose. Glucose levels on the third POD did not
have a significant independent effect on mortality (P  .1).
This further implies that the protective effects of CII are in
play at least until the third POD.
The excluded subset of 340 patients who underwent
CABG combined with valve repair or replacement had
blood cardioplegia delivery as a method of myocardial
protection. Mortality with CII was 7.4%, compared with
12.7% with SQI. Logistic regression analysis in this popu-
lation revealed a similar protective effect of CII against
death (odds ratio 0.48), although it was not significant (P 
Figure 2. Mortality among patients with DM undergoing CABG by glucose quantile. Total bar heights represent
overall mortality in each quantile. Note increase in overall mortality is overwhelmingly accounted for by increase
in cardiac-related mortality.
TABLE 2. Multivariable analysis of mortality in patients with DM undergoing CABG (N  2933)
Variable P value
Odds ratio
Value 95% confidence interval
Insulin infusion .001 0.43 0.26-0.70
Cardiogenic shock .001 5.5 2.4-12.8
Renal failure .001 3.5 1.8-6.9
Reoperation .001 2.8 1.7-5.0
Operative status .001 2.3 1.7-3.3
Age (per 1-y increment) .001 1.05 1.02-1.08
Ejection fraction (per 1% increment) .001 0.98 0.96-0.99
Unstable angina .001 3.2 1.6-6.5
History of peripheral or cerebral vascular disease .002 2.1 1.3-3.5
History of atrial fibrillation .05 2.0 1.01-3.9
Area under receiver operating characteristic curve, 0.874; Hosmer-Lemeshow goodness-of-fit, P  .6.
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.11) because of the small sample size. This suggests that the
effects of CII are not idiosyncratically related to our method
of myocardial protection for patients undergoing isolated
CABG.
External Multivariable Analysis of Mortality
To determine the effect of CII on risk-adjusted mortality,
the predicted operative risk derived from the 1996 STS risk
algorithm2 was calculated for every patient with all such
variables available (n  2834) and compared with observed
mortality (Table 3). STS-predicted mortality for the CII
group was lower than that for the SQI group. Observed
mortality with SQI did not significantly differ from that
predicted by the STS model. However, observed mortality
with CII was significantly less than predicted. These data
show a 36% reduction in the expected mortality resulting
from CII.
To further confirm the significance of the reductive effect
of CII on risk-adjusted mortality, the STS composite risk
score, was entered into a new multivariable analysis of
death along with CII. Both variables were significant (STS
risk score odds ratio 3.3, 95% confidence interval 2.7-4.0,
P  .001, CII odds ratio 0.50, 95% confidence interval
0.30-0.76, P  .005, c-statistic 0.839). Thus CII added a
protective effect against death to the constellation of risk
factors already in the STS risk model. This external model
suggests that CII conferred a 50% reduction in the risk-
adjusted mortality of patients with DM undergoing CABG.
This would translate into 21 lives saved for every 1000
patients for whom CII is effectively implemented.
The surrogate variable of average postoperative glucose
level was again found to displace the categoric variable of
CII from the external model (P  .001, odds ratio 1.02 per
1 mg/dL, c-statistic 0.853), again implicating a glycometa-
bolic mechanistic effect for CII. To account for the con-
founding influences of time and sequential controls, the
continuous variable of surgery date was once again forced
into the equation and found not to be significant (P  .9).
The temporal effect of the Portland CII protocol on
mortality among patients with DM undergoing CABG is
illustrated in Figure 3, which depicts the annualized opera-
tive mortality for all patients undergoing CABG at our
institution. Mortality among patients with DM undergoing
CABG has fallen significantly since CII implementation in
1992. Perioperative mortality among patients without DM
undergoing CABG has not changed during the same period
(slope of 0.9, P  .4). There are now no significant differ-
ences in operative mortality between patients with and
without DM undergoing CABG at this institution.
Discussion
The principal finding of this study was that CII for patients
with DM undergoing CABG independently reduced periop-
erative absolute mortality by 57% and risk-adjusted mortal-
ity by 50%. Improved survival with CII came about exclu-
sively through a reduction in cardiac-related deaths. CII had
the resultant effect of eliminating the incremental effect of
DM on mortality risk in our population of patients under-
going CABG (Figure 3).
The limitations of this study should be noted. First, this
was a nonrandomized study that compared sequential
groups of patients. Second, the use of asynchronous controls
resulted in heterogeneous study groups. This makes direct
comparison of the primary end point “death” difficult be-
cause the accompanying concomitant risks were not equally
dispersed. Finally, the prolonged time frame of this study
induces further questions concerning temporal technical bi-
ases that are difficult to measure.
Because of the automated and aggressive nature of the
Portland CII protocol, it was not feasible for us to conduct
this study in a synchronously randomized fashion. Nursing
TABLE 3. STS predicted operative risk2 versus observed
mortality (N  2834)
SQI CII
P
value*
Observed deaths .001
No. 36/673 51/2161
% 5.35 2.36
Predicted deaths (%) 4.68  7.8 3.77  5.5 .2
Observed:expected ratio .001
Value 1.14 0.64
95% Confidence
interval
0.87-1.51 0.45-0.87
P value† .3 .005
*SQI versus CII.
†Observed versus expected. Figure 3. Annualized mortality in all patients undergoing CABG
(with DM, filled diamonds, vs without DM, open circles) during
study years. Mortality in group without DM has not changed with
time. However, mortality in group with DM has decreased dra-
matically. There is currently (1995-2001) no statistical difference
between these two groups.
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comfort and confidence with the perceived safety of CII
titration in patients with what was considered to be eugly-
cemia or mild hyperglycemia was programmatically diffi-
cult. Nursing and administrative concerns about iatrogeni-
cally induced hypoglycemia in this high-visibility patient
population had first to be assuaged. This was accomplished
gradually, first in the ICU and then on the telemetry floor,
through rigorous and repeated in-service training confer-
ences. When the protocol was finally functioning smoothly
in the desired units, target glucose levels were then gradu-
ally lowered. As can be seen in Figure 1, tight perioperative
glycemic control took years for full implementation and
achievement. Once the other beneficial effects of tight glu-
cose control on patient outcomes (decreased wound infec-
tions, decreased length of stay) became known,14,16,18 both
we and the institutional review board considered a synchro-
nously randomized study with SQI control subjects uneth-
ical. Thus the nonrandomized nature of this study at this
institution is and must remain a statistical design flaw to
which some reviewers may object.
Although these technical limitations cannot be fully ab-
rogated, we sought to minimize temporal bias and hetero-
geneity through appropriately sound statistical methods.
Multivariable analyses serve well to smooth out baseline
constitutional differences between groups.19,20 A well-ac-
cepted, nationally derived, external risk model2 was used to
normalize both constitutional makeup and temporal biases.
All multivariable analyses, both internal and external, con-
tinued to reveal the protective significance of CII.
The long time frame of this study was necessary to
accumulate enough outcome data from patients with DM
undergoing CABG to power the study effectively. We ac-
cumulated an average of 237 patients with DM undergoing
CABG per year toward the goal of 4000 patients, the
number that would have been required to detect a 30%
decrease in an overall mortality of 5%.
Temporal bias is further excluded by the following facts:
(1) date of surgery had no significant effect on either mul-
tivariable model and (2) mortality among patients without
DM undergoing CABG did not change with time. Nonethe-
less, we cannot rule out a conglomeration of minute im-
provements in operative technique during the 15-year study
period that may have contributed to a decline in DM-
associated mortality.
Analysis of average postoperative glucose level does not
carry with it the biases of nonrandomization and asynchro-
nous controls. Rather, it is a direct measure of the underly-
ing glycometabolic state of the myocardium that in itself is
devoid of group selection and temporal bias. Thus it is
important to note that in both multivariable models mortal-
ity was also independently linked with average postopera-
tive glucose level. This relationship held regardless of the
study group into which the patient was entered.
This study was not intended to definitively establish a
biochemical mechanism of action for the mortality-reducing
effects of CII. However, on the basis of previously pub-
lished literature, we have theorized that alterations in myo-
cardial metabolism in ischemic patients with DM undergo-
ing CABG are detrimental, whereas insulin-enhanced
alterations in myocardial energy formation are one of the
potential mechanisms for the favorable effects of CII on
mortality. The following subsections of the discussion are
offered as an exposition of previously published works in
this field that support this theory.
Normal Myocardial Energetics
The myocardium has been described as an “omnivore”
because it is able to use any of several substrates for the
production of ATP to power the continuous cycle of ven-
tricular contraction and relaxation. The known substrates
include free fatty acids (FFAs), glucose, pyruvate, lactate,
ketones, and even amino acids.21 In normal nondiabetic,
nonischemic myocardium, 60% of ATP production is de-
rived from lipolysis and -oxidation of palmitate or FFAs,
whereas 35% is derived from glycolytic sources.22 Both
glycolysis and FFA -oxidation eventually produce acetyl
coenzyme A. This is the primary substrate that produces
hydrogen ions for oxidative phosphorylation through the
Krebs cycle in the mitochondria. Feedback mechanisms
related to the concentration of acetyl coenzyme A in the
mitochondria ensure a balance between these two path-
ways.23,24
Anerobic glycolysis occurs in the cytosol and produces
pyruvate while regenerating cytosolic ATP, which is critical
for the maintenance of cell membrane integrity.25 It is also
used to phosphorylate extracellular glucose for active trans-
port into the cytosol and subsequently on to glycolysis.26
Pyruvate passively diffuses into the mitochondria, where it
is decarboxylated to acetyl coenzyme A by pyruvate dehy-
drogenase complex (PDH).24 Oxidative glycolysis can then
be completed by the Krebs cycle. In the absence of insulin,
PDH activity decreases in the mitochondria, pyruvate builds
up in the cytosol, and excess pyruvate is converted to
lactate. The reduction and decarboxylation of pyruvate by
PDH thus becomes the rate-limiting step for further oxida-
tive glycolysis. Lipolysis-derived FFAs are actively trans-
ported into the mitochondria, where they undergo -oxida-
tion to produce acetyl coenzyme A. Increased levels of
FFA-derived acetyl coenzyme A inhibit PDH and thus
inhibit oxidative glycolysis.24
Alterations in Myocardial Energetics in Patients With
DM Undergoing CABG
In patients with DM undergoing CABG, myocardial metab-
olism is negatively altered by both the ischemic and diabetic
pathologic states. In patients without DM, the supply of
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molecular oxygen is limited during periods of ischemia.
FFA oxidation is inhibited, and oxygen-efficient glycolytic
ATP production predominates. In patients with poorly con-
trolled DM undergoing CABG, however, this is not possible
because glycolysis is hormonally inhibited and lipolysis is
paradoxically enhanced.
Deficiencies in insulin bioavailability increase serum
concentrations and myocardial use of FFAs, further inhib-
iting glucose use. Serum glucose levels consequently rise in
proportion to the underlying glycometabolic defect in the
cells. A paucity of bioavailable insulin in the cell also slows
phosphorylation of glucose and fails to activate PDH.27
Glycolysis is thus inhibited in diabetic myocardium, and
FFA oxidation is paradoxically and detrimentally activated.
Ischemic cardiomyocytes must now derive as much as 90%
of their energy from FFA metabolism.13 Because of limited
oxidative capacity, the FFAs taken up by the myocardium
are not completely metabolized. FFAs and their partially
-oxidized intermediates accumulate in the myocardium.
These compounds are known to decrease contractility and
increase the incidence of ventricular arrhythmias.28,29 Al-
though FFAs produce more ATP than does glucose does
during complete aerobic oxidation, they do so at the expense
of a higher rate of oxygen consumption.25 This further
increases myocardial oxygen consumption and exacerbates
cellular ischemia at a time when oxygen supply is limited.
Glycolysis-derived cytosolic ATP preferentially supports
cell membrane ion transport and hence helps to preserve
cellular integrity.25 Even after successful revascularization
and reperfusion of the underlying ischemia, postoperative
deficiencies in glucose metabolism persist in patients with
poorly controlled DM. The persistent lack of glycolysis-
derived ATP prolongs membrane destabilization and leads
to increased cellular edema and arrhythmogenic potential.28
In summary, serum glucose level may act as a “fuel
gauge” that varies inversely with the ability of the cardio-
myocyte to effectively absorb and use that fuel. In patients
with poorly controlled DM undergoing CABG, glycolysis is
inhibited, serum glucose is elevated, FFA metabolism is
paradoxically activated, and FFA intermediates accumulate
in myocardial cells. The serum glucose level thus reveals
the underlying glycometabolic state of the myocardium to
the astute clinician.
Mechanism of Action of CII
The administration of insulin to the hyperglycemic patient
with DM undergoing CABG reverses the aforementioned
metabolic deficiencies. Exogenous intravenous insulin
causes both intracellular and extracellular insulin levels to
rise. As intracellular insulin rises, PDH is activated.30 As
mitochondrial pyruvate levels fall, cytosolic pyruvate is
depleted by diffusion, opening up the pathway for increased
cytosolic glycolysis. Glycolysis, again stimulated by insu-
lin, replenishes cytosolic ATP, which is in turn used to
stabilize cellular membranes, phosphorylate extracellular
glucose for transport into the cell, and facilitate membrane
ion transport. These processes are crucial to endothelial,
vascular smooth muscle, and myocardial cellular integrity.31
Blood glucose levels are in turn lowered as myocardial
glucose uptake is enhanced.27 Preservation of myocyte,
endothelial and smooth muscle cell membranes results in
decreased cellular edema, reduced microvascular compres-
sion, and prevention of the no-reflow phenomenon that may
occur during reperfusion.32 The preservation of endothelial
integrity and vascular smooth muscle function may also
improve myocardial function by increasing native myocar-
dial perfusion and by lowering systemic and pulmonary
afterload resistances.31
Intracellular glycerol esterifies intracellular FFAs, pre-
venting them from being transported into the mitochon-
dria.32 In addition, the increase in mitochondrial acetyl
coenzyme A derived from active glycolysis inhibits the
carnitine-assisted transport of FFAs into the mitochondria.24
This explains how increases in glucose oxidation are able to
downwardly regulate myocardial FFA oxidation. Myocar-
dial oxygen consumption is thus decreased by shutting
down the -oxidation of FFAs. Accumulation of the nega-
tively inotropic intermediaries of FFA oxidation ceases,28
free radical formation stops, and myocardial efficiency and
function improve.34 Insulin may further protect subcellular
function by serving as a scavenger of free radicals generated
during the ischemia-reperfusion process.34 Insulin thus di-
rectly enhances glycolysis, mediates active transport of
phosphorylated glucose across the cell membrane, and in-
hibits further lipolysis, preventing buildup of toxic interme-
diates.27,35
The clinical effects of the CII protocol may also be
related to other sequelae of insulin administration on the
myocardium, such as increased uptake of potassium or
magnesium into the myocyte. It is also possible that some of
the beneficial outcomes seen with CII are related to its
effects in tissues other than the heart, such as improved
energetics of skeletal muscle, lower circulating lactate lev-
els during the interval on cardiopulmonary bypass, and
improved endothelial function, as mentioned previously. It
is important to note that our study provides no data on
serum insulin levels, FFA levels, intracellular metabolite
levels, myocardial ATP levels, enzyme activity levels, or
glycolic rates. Therefore a definitive, indirect relationship
between serum glucose levels and myocardial glycolysis
rates is not proved by our study.
Clinical Evidence
There is, however, abundant clinical evidence that glyco-
metabolic processes indeed play a role in critically ill pa-
tients. Not only is DM a risk factor for CABG mortality,1-3
it also independently predicts higher incidences of postop-
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erative arrhythmias, low cardiac output syndrome, and in-
tra-aortic balloon pump use.36-38
Glucose does appear to be a superior substrate during
periods of myocardial ischemia.32 However, that substrate
must be made biologically available by an adequate supply
of insulin. In the Diabetes and Insulin-Glucose Infusion in
Acute Myocardial Infarction study, Malmberg and associ-
ates7 demonstrated that intensive glycometabolic control
with CII after MI in patients with DM led to improved
long-term survival.7 The Estudios Cardiologicos Latino-
america study group demonstrated a 66% reduction in acute
post-MI mortality with GIK modulation in addition to reper-
fusion.9
GIK solutions in acutely ischemic myocardium have
been shown to enhance contractility,39 decrease arrhyth-
mias, and decrease myocardial oxygen consumption.27 Rao
and colleagues11 have shown that insulin-enhanced cardio-
plegia improves post-arrest stroke work and cardiac indices.
In addition, it hastens the return of myocardial oxygen
extraction to baseline after cardioplegic arrest.
Lazar and associates’ extensive clinical and experimental
work with GIK40 has shown us that this therapy limits
postischemic tissue necrosis, infarct size, and acidosis, and
it prevents myocardial stunning. Clinically this has resulted
in increased cardiac indices, decreased weight gain, short-
ened ventilator times, and reduced atrial arrhythmias among
patients undergoing CABG who require urgent revascular-
ization for ongoing ischemia.10 In patients with DM under-
going CABG, GIK had the additional effect of shortening
hospital stay.12 Recently GIK solutions have also been
shown to improve left ventricular contractility and ventricu-
loarterial coupling in diabetic sheep.41
Although they were not the primary end points of the
current study, there were univariate reductions in the inci-
dences of new-onset atrial fibrillation and low cardiac out-
put syndrome with the use of CII (Table 1). These findings
further support our theoretic assertion that alterations in
glycometabolic function play an etiologic role in the out-
come alterations that we have seen.
Portland CII Protocol
We propose that the glycometabolic state of the cardiomy-
ocyte is the final and true variable that directly affects
outcomes in patients with DM undergoing CABG. The
serum glucose level merely illustrates the level of the un-
derlying glycometabolic deficiency for the clinician. The
Portland CII protocol is a directed therapy designed to
normalize the glycometabolic state of the myocardium in
patients with DM.
The Portland CII protocol is similar to GIK therapy in
that insulin and potassium are iatrogenically administered to
safely enhance glucose use. However, the Portland CII
protocol is an insulin therapy that is precisely tailored to
correct the specific glycometabolic defect that exists in each
patient. Every patient with DM has a unique degree of
glucose-insulin mismatch and an accompanying unique gly-
cometabolic deficiency. Exogenous glucose is not “force
fed” to the cells in an attempt to turbo charge ATP produc-
tion and reduce FFA use, as it is with GIK regimens in
patients without DM. Rather, excess endogenous glucose is
used as myocardial substrate. Thus the clinician can directly
monitor the cellular metabolic effectiveness of CII therapy
by monitoring serum glucose levels. The induced physio-
logic hyperinsulinemia alleviates the glycolytic deficiency
in direct proportion to its severity.
Previous studies have failed to demonstrate a clinical
survival benefit from the administration of GIK to patients
undergoing CABG.10,12 There are several potential method-
ologic explanations. Most clinical GIK studies have been
done in ischemic patients without DM. Unlike patients with
DM undergoing CABG, these patients do not have a per-
sistent and prolonged glycometabolic defect after reperfu-
sion. Even the beneficial effects of insulin-enhanced cardio-
plegia are dissipated by 8 hours in patients without DM
undergoing CABG.11 Furthermore, with the addition of
exogenous glucose there is no clinical mechanism of mon-
itoring the effectiveness of cellular glucose loading to in-
crease oxidative glycolysis. In addition to applying a non-
tailored glycometabolic therapy to patients without DM,
most studies have been underpowered to detect small dif-
ferences in mortality.
In Lazar and associates’ study on patients with DM,12
GIK was used in the operating room and only for 12 hours
after the operation in the ICU. Because glycolysis-derived
ATP is critical to myocardial, endothelial, and smooth mus-
cle membrane stability, whereas accumulation of FFA in-
termediates is detrimental to these cells’ function,32 we
believe that glucose metabolism should be maintained at
optimum levels for at least the first 2 PODs. This has now
been elucidated by our findings that daily average glucose
levels are significant independent predictors of death until
the third POD, when their significance ceases. Maintenance
of tight glycometabolic control throughout this period of
maximum postoperative cellular edema should serve to
stabilize cell membranes, enhance endothelial function, and
reduce further fluid accumulation.
There is one previously published study showing a sur-
vival advantage with CII in postoperative surgical pa-
tients.42 In that study, CII was used in a heterogeneous
group of hyperglycemic patients in an ICU setting. Insulin
was titrated to a euglycemic target of 80 to 110 mg/dL, and
exogenous glucose was not used. Most interestingly, the
survival advantage with CII was only seen among patients
who remained in the ICU and continued to receive CII for
5 days or longer. This finding corroborates our assertion that
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strict glycometabolic correction and continuation of CII
therapy for the day of surgery and at least the first 2 PODs
are both key elements in the clinical success of our protocol.
Our study is the first to show a decrease in CABG
mortality with insulin infusions. We believe that the previ-
ously published basic scientific literature supports our pos-
tulate that this mortality reduction has been brought about
by enhanced glycometabolic control, with a resultant reduc-
tion in FFA intermediates. This nonsurgical intervention
reduced both absolute and risk-adjusted mortalities in pa-
tients with DM undergoing CABG. The striking relation-
ship of glucose levels to cardiac-related death also impli-
cates a potential myocardial glycometabolic etiology for the
improved survival. These findings corroborate our method-
ologic theory that myocardial energetics are enhanced by
strict glycometabolic control.
Summary
Perioperative glycometabolic control with CII on the day of
surgery and through the first 2 PODs reduced absolute
mortality in our population of patients with DM undergoing
CABG by 57%. The reduction in mortality was completely
accounted for by a reduction in cardiac-related deaths. Con-
versely overall mortality, specifically cardiac-related mor-
tality, increased significantly in association with rising post-
operative glucose levels. These findings implicate enhanced
myocardial glycometabolic function as the underlying
source of improved outcomes with CII. Strict glycometa-
bolic control with CII normalized CABG mortality among
patients with DM in our institution to that of the nondiabetic
population. CII decreased risk-adjusted mortality by 50%
and thus exerted a protective effect on mortality indepen-
dent of the constellation of risk factors in the STS CABG
risk model.
Conclusion
We conclude that DM per se is not a true risk factor for
death after CABG. Rather, we propose that it is the under-
lying glycometabolic state of the myocardium that indepen-
dently affects postoperative mortality. Excellent glycometa-
bolic control can be safely achieved through the use of a CII
in the perioperative period. Insulin infusions may induce
biochemical changes in the production of myocardial ATP
that are beneficial to cellular integrity and endothelial and
ventricular function. This is amplified clinically into re-
duced postoperative mortality. Insulin infusions in patients
with DM undergoing CABG reduce mortality and eliminate
the incremental increase in risk-adjusted mortality previ-
ously ascribed to DM. Insulin infusions should become the
standard of care for glycometabolic control in patients with
DM undergoing CABG.
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Appendix
Portland CII Protocol (Version 2001)
Target blood glucose is 100 to 150 mg/dL.
1. Start Portland protocol during surgery and continue through
7 AM of the third POD. Patients who are not receiving enteral
nutrition on the third POD should remain on this protocol
until receiving at least 50% of a full liquid or soft American
Diabetes Association diet.
2. For patients with previously undiagnosed DM who have
hyperglycemia, start Portland protocol if blood glucose is
greater than 200 mg/dL. Consult endocrinologist on POD 2
for DM workup and follow-up orders.
3. Start infusion by pump piggyback to maintenance intrave-
nous line as shown in Appendix Table 1.
4. Test blood glucose level by finger stick method or arterial
line drop sample. Frequency of blood glucose testing is as
follows:
a. When blood glucose level greater than 200 mg/dL, check
every 30 minutes.
b. When blood glucose level is less than 200 mg/dL, check
every hour.
c. When titrating vasopressors, (eg, epinephrine) check every
30 minutes.
d. When blood glucose level is 100 to 150 mg/dL with less
than 15 mg/dL change and insulin rate remains unchanged
for 4 hours (“stable infusion rate”), then you may test
every 2 hours.
e. You may stop testing every 2 hours on POD 3 (see items
1 and 8).
f. At night on telemetry unit, test every 2 hours if blood
glucose level is 150 to 200 mg/dL; test every 4 hours if
blood glucose level is less than 150 mg/dL and “stable
infusion rate” exists.
5. Insulin titration according to blood glucose level is per-
formed as follows
a. When blood glucose level is less than 50 mg/dL, stop
insulin and give 25 mL 50% dextrose in water. Recheck
blood glucose level in 30 minutes. When blood glucose
level is greater than 75 mg/dL, restart with rate 50% of
previous rate.
b. When blood glucose level is 50 to 75 mg/dL, stop insulin.
Recheck blood glucose level in 30 minutes; if previous
blood glucose level was greater than 100 then give 25 mL
50% dextrose in water. When blood glucose level is
greater than 75 mg/dL, restart with rate 50% of previous
rate.
c. When blood glucose level is 75 to 100 mg/dL and less than
10 mg/dL lower than last test, decrease rate by 0.5 U/h. If
blood glucose level is more than 10 mg/dL lower than last
Appendix TABLE 1. Parameters for CII under Portland pro-
tocol
Blood glucose
(mg/dL)
Intravenous
insulin bolus
(units)
Initial insulin rate (U/h)
Non–insulin
dependent DM
Insulin
dependent DM
80-119 0 0.5 1
120-179 0 1 2
180-239 0 2 3.5
240-299 4 3.5 5
300-359 8 5 6.5
360 12 6.5 8
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test, decrease rate by 50%. If blood glucose level is the
same or greater than last test, maintain same rate.
d. When blood glucose level is 101 to 150 mg/dL, maintain
rate.
e. When blood glucose level is 151 to 200 mg/dL and 20
mg/dL lower than last test, maintain rate. Otherwise in-
crease rate by 0.5 U/h.
j. When blood glucose level is greater than 200 mg/dL and
at least 30 mg/dL lower than last test, maintain rate. If
blood glucose level is less than 30 mg/dL lower than last
test (or is higher than last test), increase rate by 1 U/h and,
if greater than 240 mg/dL, administer intravenous bolus of
regular insulin per initial intravenous insulin bolus dosage
scale (see item 3). Recheck blood glucose level in 30
minutes.
k. If blood glucose level is greater than 200 mg/dL and has
not decreased after three consecutive increases in insulin,
then double insulin rate.
b. If blood glucose level is greater than 300 mg/dL for four
consecutive readings, call physician for additional intra-
venous bolus orders.
6. American Diabetes Association 1800-kcal diabetic diet starts
with any intake by mouth.
7. Postmeal subcutaneous Humalog insulin supplement is given
in addition to insulin infusion when oral intake has advanced
beyond clear liquids.
a. If patient eats 50% or less of servings on breakfast, lunch,
or dinner tray, then give 3 units of Humalog insulin
subcutaneously immediately after that meal.
b. If patient eats more than 50% of servings on breakfast,
lunch, or supper tray, then give 6 units of Humalog insulin
subcutaneously immediately after that meal.
8. On third POD, restart preadmission glycemic control medi-
cation unless patient is not tolerating enteral nutrition and is
still receiving an insulin drip.
Discussion
Dr Terrence M. Yau (Toronto, Ontario, Canada). I congrat-
ulate Furnary and colleagues on identifying a subgroup of patients
undergoing CABG who are clearly at higher risk for perioperative
morbidity and mortality and for devising a physiologically based,
if clinically unproven, method to improve clinical outcomes.
Interest in metabolic enhancement of the ischemic myocardium
started as early as 1965, when Sodi-Pollares observed the benefi-
cial effects of a continuous GIK infusion on the electrocardio-
graphic changes after acute MI. Early excitement about this form
of therapy, both as a continuous intravenous infusion and as a
bolus cardioplegic additive, waned as several small randomized
trials in a variety of cardiovascular settings failed to demonstrate a
consistently protective effect. Caution was then introduced by
David Hearse in 1978, when he documented an exacerbation of
ischemic injury in rats rendered hyperglycemic during the period
of cardioplegic arrest.
Recently our group in Toronto and Lazar’s group in Boston
have revisited the concept of perioperative metabolic enhancement
with GIK solutions. In addition, the Portland group of Furnary and
colleagues have performed an extensive series of investigations
into the effects of insulin on clinical outcomes in patients with
DM, including this analysis. However, one must exercise caution
before interpreting the results of any clinical study, particularly a
nonrandomized retrospective observational review.
Furnary and colleagues are to be commended for a thorough
statistical analysis of their data, but as they indicate in their article,
no amount of statistical adjustment can adequately replace the
robust design of a prospective, randomized study. Any post hoc
statistical adjustment is only as good as the variables that are
entered into that model. One approach to remove this bias is to
perform a propensity analysis and then adjust your findings ac-
cording to the likelihood of a given patient with DM receiving
either SQI or CII.
I have a few questions for Dr Furnary. Your institution favors
the use of intermittent fibrillatory arrest for perioperative myocar-
dial protection. Do you believe that your observed differences
would still be significant if your surgeons used blood cardioplegia?
In addition, it appears from your data that the primary benefit of
CII was a reduction in cardiac-related mortality relative to patients
receiving SQI. However, there was no difference in the postoper-
ative use of inotropes or in postoperative low cardiac output
syndrome in these patients. You do not mention the prevalence of
perioperative MI. Was your observed benefit due to reduction in
postoperative arrhythmias, as Lazar has previously shown, or truly
an improvement in myocardial function, as you imply in your
article?
You comment that your institutional review board would no
longer consider it ethical to perform a prospective randomized trial
on CII in patients with DM. Are you considering such a trial in
patients without DM where you could randomly assign them to
receive CII with tight glucose control versus placebo? You may
wish to design such a trial to specifically examine the prevalence
of postoperative arrhythmias.
Finally, although I personally favor the use of perioperative
insulin, I must report to the audience that a large multicenter
prospective clinical trial, to be published shortly in our Associa-
tion’s journal, failed to demonstrate a clinical benefit of insulin-
enhanced cardioplegia in patients undergoing urgent CABG. We
do believe, however, that perhaps the true benefit of insulin infu-
sion may be seen in patients with moderate to severe left ventric-
ular dysfunction, and we are currently enrolling patients in a
randomized evaluation of that intervention.
A substudy of our trial on patients undergoing urgent revascu-
larization failed to demonstrate any reduction in the postoperative
incidence of supraventricular tachyarrhythmias. These trials have
used insulin only as a cardioplegic additive and failed to admin-
ister the drug beyond the operating room. It is conceivable that
following a protocol similar to that described today by the Portland
group might result in clinically meaningful benefit. I believe that
such a prospective randomized study is worthy of consideration.
Dr Furnary. I will take your questions in order. We do use
intermittent fibrillatory arrest as a method of myocardial protec-
tion. The periods of arrest range between 5 and 12 minutes, after
which the heart is reperfused. We have not seen a difference in
mortality in our CABG population without DM and that predicted
by the STS risk model. As a matter of fact, our observed/expected
mortality ratio in that population is consistently in the 0.5 to 0.7
range. So I do not believe that mortality reduction from insulin
infusion is unique to its combination with intermittent fibrillation.
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I believe that the mortality benefits are seen along with the use of
cardioplegia as well.
Backing up that statement is the fact that this study focused
only on patients undergoing isolated CABG. When we looked at
the excluded subset of 400 additional patients who underwent
combined CABG and valve replacement and who had blood car-
dioplegia delivery as a method of myocardial protection, almost
the exact same multiple logistic regression came up, with insulin
being protective against postoperative death.
In answer to your second question, we actually do know the
incidences of low cardiac output and arrhythmia. We do not know
the incidence of postoperative MI. I would point out that although
this was a nonrandomized study, it was a prospective interven-
tional study (not a retrospective observational one) in which we
collected our data in a prospective fashion.
The incidence of low cardiac output in the entire population
was 11%. The graph of the relationship of low cardiac output to
increase in glucose levels exactly mirrors the graph of increasing
mortality with increasing glucose levels. Therefore I believe that
ventricular function is a key component in the improved survival
seen with insulin infusions, which strictly control glucose levels.
In addition, arrhythmias are much more prevalent with high glu-
cose levels. And when we examine the biochemical energetics of
the myocardial cell and look at what is happening at the cellular
level, it is easy to see why this would be so. As a matter of fact,
in Lazar’s published work with GIK in patients with DM, he also
noted a decreased incidence of arrhythmias, including atrial ar-
rhythmias such as atrial fibrillation.
In terms of a randomized trial, at this point we certainly could
not ethically perform a randomized trial in our institution compar-
ing CII and SQI. We have considered doing a randomized trial
comparing extremely low glucose levels, perhaps a target range of
80 to 110 mg/dL, with our current target range of 100 to 150
mg/dL.
As you can see, our protocol has been modified with time. The
goal at the outset of this project was to gradually and safely
establish euglycemia in all patients with DM in an attempt to
modify outcomes and normalize those outcomes to those of the
population without DM. So theoretically we could randomly as-
sign one group of patients to a target range between 80 and 120
mg/dL and another group to a target range between 150 and 200
mg/dL. The problem comes in that the power analysis tells us that
to show a 50% decrease in mortality between those two groups, we
are going to need around 5000 patients, and we only accumulate
about 200 patients with DM undergoing CABG per year. Thus
such as study would have to be done in a multi-institutional setting.
Finally, the fact that insulin-enhanced cardioplegia shows no
overall clinical benefits in your upcoming study is not surprising to
me. It reinforces the fact that insulin therapy must be continued for
some time after the operation to show a clinical effect on mortality.
In Rao’s previous article on insulin-enhanced cardioplegia, there
was no benefit to ventricular function seen beyond 8 hours after the
operation in patients without DM. And one must further under-
stand that patients with DM undergoing CABG not only have the
detriment of ischemia of the myocardium but also the ongoing,
persistent detriment of the lack of effective oxidative glycolysis.
Those two things combined are what make the patient with DM
unique, not only in surgery but in the postoperative period as well.
And that is why we believe, as was published in the New England
Journal of Medicine this past November, that the prolonged use of
insulin and thus prolonged normoglycemia are important in im-
proving clinical outcomes.
Dr Richard M. Engelman (Springfield, Mass). I congratulate
Furnary and colleagues on a sophisticated presentation and on
bringing this subject, which has important implications for all of us
in the care of the patient with DM, to our attention. I have had an
opportunity to review the manuscript and thus can speak from
some data.
One point that I would like to emphasize is the potential
importance of intraoperative glycemia control. This was not actu-
ally controlled, as pointed out by Furnary and colleagues, until
1996, and the absence of rigorous control of the intraoperative
blood sugar may be a factor in the results reported here. Intraop-
erative hyperglycemia in most hospitals is treated by the anesthe-
siologist without surgical involvement or adherence to a protocol.
I have the impression that intraoperative hyperglycemia is a factor
in leading to depressed myocardial recovery. The most frequent
cause of death in the series, as the article points out, was cardiac
related. Dr Furnary, I would appreciate your comments on that.
A question that I have relates to the actual solution that you
used for CII. We are about to enter a protocol for a glycemic
control with a glucose-insulin solution, and I would be interested
in knowing what your solution was and whether you believe
glucose added to the insulin has any advantage in preventing
hypoglycemia or simply makes glycemic control more difficult.
My final question relates to optimal glycemic level. You have
now reduced your blood sugar goal to 120 mg/dL, as you just
indicated, from a high of 200 mg/dL initially, and the recently
published Belgium study, as you mentioned in the New England
Journal of Medicine, actually used a goal of 80 to 110 mg/dL. As
you have shown no difference in mortality related to the year of
this study once the patients were receiving the CII, why do you
believe that a lower glycemic level is actually preferable, or is less
than 200 mg/dL actually satisfactory?
Dr Furnary. First of all, I wholeheartedly agree with your
assertion that intraoperative hyperglycemia is paramount in affect-
ing outcomes, especially cardiac-related outcomes. At the current
time we manage intraoperative hyperglycemia along with the
anesthesiologists and actually write the numbers up on the board
so that everybody can see what they are. It was somewhat difficult
to get that started, because some anesthesiologists preferred just to
give bolus insulin and preferred not to institute a drip. But after we
got it going, it really had a marked effect on postoperative glucose
control and hence clinical outcomes, and I could not agree more
with your statement.
The solution that we currently use is 125 units of regular insulin
in 250 mL isotonic saline solution. The reason that we use isotonic
saline solution is we use it as a piggyback infusion along with
another intravenous drip. When we were using 5% dextrose in
water solutions as a maintenance intravenous solution, some pa-
tients without DM would become hyperglycemic because of the
combined stresses of surgery in the face of added glucose. As
glucose levels rose in these patients without DM, they would get
started on an insulin drip. When they were transferred to the floor
and as they started eating, the 5% dextrose in water maintenance
infusions were discontinued; however, the insulin infusions con-
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tinued to run. These patients without DM would thus end up with
hypoglycemia as they started eating and the 5% dextrose in water
intravenous drip was stopped, and that was not good. To avoid that
situation, we switched to isotonic saline solution as our standard
intravenous solution. We thus decreased the incidence of iatro-
genic hyperglycemia in patients without DM and also decreased
the incidence of hypoglycemia on the telemetry floor.
The optimal glucose level for enhancing clinical outcomes is
uncertain. I can tell you that if you keep it below 150 mg/dL, you
will certainly see the effects on wound infection rates that we have
previously demonstrated and the reductive effect on mortality
demonstrated today. The intent of lowering it to 120 mg/dL is to
complete our original intent of this study, which was to normalize
glucose levels in these patients and thus try to normalize heart
surgery outcomes of patients with DM to those of the general
population. What I believe lowering the target levels may do is to
lower the incidence of atrial fibrillation, and we are already seeing
a trend in that direction.
But the two key elements here for anyone putting this type of
protocol together are glucose target levels and duration of the
infusion. Glucose levels should be tightly controlled at near nor-
moglycemia or euglycemia, and the insulin should be used for a
period of at least 3 days (the day of surgery and the first and second
PODs) to effect the outcomes that we have described. And that
rationale has to do, as explained in the article, with the mechanistic
effects of glycolysis-derived cytosolic ATP on membrane function
and integrity in the postoperative period.
Dr Harold I. Lazar (Boston, Mass). Three years ago, we had
the privilege of presenting some data on patients with DM. We
used a modified GIK solution, and we did find significant improve-
ment, with reduction in atrial fibrillation, weight gain, improved
cardiac index, and decreased length of stay.
My comments are related to the mechanism responsible for the
beneficial effects of GIK in these patients. The mechanism may not
necessarily be due to the increased availability of ATP. In the last
2 years we have had the opportunity to continue this study and
actually measure not only the level of glucose, which we have
maintained between 120 and 180 mg/dL, but also FFAs, triglyc-
erides, and lactate. We found that there is a beneficial effect of
GIK in decreasing FFAs. These beneficial effects may not all be
related to increased availability of ATP but rather to improvement
in endothelial function.
My second point is when you give this solution. It is important
to start it in the operating room during induction and continue it for
at least 12 to 24 hours. This explains why Dr Yau’s insulin
cardioplegia had very little effect. It was only given for a short
period. Clearly, this metabolic enhancement has to be given for a
longer period.
With respect to the other comment about doing a study in
patients without DM, as you know, we have already done that.
Certainly insulin and glucose together in a population without DM
are also extremely effective, especially in patients with unstable
and emergency CABG surgery.
I think that it is not ethical to randomly assign these patients
anymore, because tighter glycemic control for these patients leads
to better clinical outcomes. We have found that using 5% dextrose
in water and insulin in a drip has no detrimental effect. So these
people can have a little bit of glucose. In fact, one of the studies
that we are currently doing in patients with DM is to see whether
there is any advantage in adding glucose to insulin, versus just an
insulin drip alone.
Dr Furnary. Dr Lazar, it is a privilege to have you comment
on this study. I could not agree with you more that there is more
going on than just intracellular ATP modification, and we go into
many of the other probable mechanisms in the article. In an
8-minute presentation it is difficult to cover all the possible bio-
chemical mechanisms. But the elimination of the toxic intermedi-
ates of FFA oxidation no question plays a key role in eliminating
the no-reflow phenomenon, improving endothelial function, and
stabilizing cellular membranes.
However, I would take that comment and go into your second
question, and this I think is where we disagree. It is my firm belief
that insulin infusions should be used not just for 12 hours after the
operation, as in your study, but for longer than 48 hours. Thus, for
consistency in this regard, we discontinue our insulin infusion
protocol on the morning of the third POD. The rationale for that
duration is that, as we all know from our basic surgical training,
the first 48 postoperative hours is the period of maximal edema
accumulation. Decreased FFA intermediates and increased cyto-
solic ATP are extremely important in stabilizing membrane func-
tion. Thus to achieve the maximum benefits on those parameters
that you have shown in your articles to be potentially influenced by
insulin metabolic modification—decreased edema, decreased in-
tubation times, and decreased weight gain—one must use the
protocol through the first 3 PODs. That is the duration through
which we believe this protocol must be used. I do not think that the
same mortality-reducing results would be seen if the protocol were
used for a shorter time than 3 PODs.
Finally, with regard to whether random assignment is ethical,
we can look at it this way. We in medicine hold ourselves to a high
standard so as not to harm our patients while obtaining definitive
answers to our scientific questions. Because of this, we prefer to
use randomized controls. But this study and this protocol was a
process of continuous quality improvement with known and on-
going outcome improvements in infection control and length of
stay; to randomize the protocol at this point would be like having
the automobile industry randomize the placement of seat belts in
the late 1970s. Think of the countless people who would have died
in that process before that industry said, “Oh, seat belts work, let’s
put them in every car.” So I think that we, especially today with the
social and economic backgrounds against which we currently work
in medicine, have to do studies and make decisions that make
pragmatic sense for our patients and their lives, while still deriving
what scientific data we can from those studies in a sensible way.
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